Connection

JOANNA JANKOWSKY to Amyloid beta-Peptides

This is a "connection" page, showing publications JOANNA JANKOWSKY has written about Amyloid beta-Peptides.
Connection Strength

3.785
  1. Gene therapy using A? variants for amyloid reduction. Mol Ther. 2021 07 07; 29(7):2294-2307.
    View in: PubMed
    Score: 0.610
  2. Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease. Hum Mol Genet. 2019 06 15; 28(12):2014-2029.
    View in: PubMed
    Score: 0.542
  3. Combination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med. 2018 05 07; 215(5):1349-1364.
    View in: PubMed
    Score: 0.499
  4. Discrete Pools of Oligomeric Amyloid-? Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. Am J Pathol. 2018 03; 188(3):739-756.
    View in: PubMed
    Score: 0.489
  5. Wild-type neural progenitors divide and differentiate normally in an amyloid-rich environment. J Neurosci. 2013 Oct 30; 33(44):17335-41.
    View in: PubMed
    Score: 0.367
  6. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci. 2011 Mar 16; 31(11):4124-36.
    View in: PubMed
    Score: 0.306
  7. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem. 2007 Aug 03; 282(31):22707-20.
    View in: PubMed
    Score: 0.236
  8. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005 Dec; 2(12):e355.
    View in: PubMed
    Score: 0.212
  9. Combination of A? Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition. Am J Pathol. 2017 Dec; 187(12):2886-2894.
    View in: PubMed
    Score: 0.120
  10. Quaternary Structure Defines a Large Class of Amyloid-? Oligomers Neutralized by Sequestration. Cell Rep. 2015 Jun 23; 11(11):1760-71.
    View in: PubMed
    Score: 0.103
  11. NF?B-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron. 2015 Jan 07; 85(1):101-115.
    View in: PubMed
    Score: 0.099
  12. Astrocytic Sox9 overexpression in Alzheimer's disease mouse models promotes A? plaque phagocytosis and preserves cognitive function. Nat Neurosci. 2026 Jan; 29(1):88-99.
    View in: PubMed
    Score: 0.053
  13. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci. 2005 May 25; 25(21):5217-24.
    View in: PubMed
    Score: 0.051
  14. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004 Jan 15; 13(2):159-70.
    View in: PubMed
    Score: 0.046
  15. Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr Neurol Neurosci Rep. 2002 Sep; 2(5):457-64.
    View in: PubMed
    Score: 0.042
  16. Hyper-expression of human apolipoprotein E4 in astroglia and neurons does not enhance amyloid deposition in transgenic mice. Hum Mol Genet. 2001 Oct 15; 10(22):2525-37.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.